Hi everyone, first time poster here long time reader.
I have been invested in CYDY since March of 2020. I work in an elderly care facility, and when covid hit I began doing as much research as I could on it. Like others on this board, my research led me to Leronlimab (LemonLime as my sister affectionately calls it hence the alias).
I wish my first post could be positive and upbeat, but unfortunately the diagnosis of cancer in a loved one is what prompted me to make an account.
My brother-in-law, who is a physician and has dedicated his life to helping others as a family practitioner, is heading to the Mayo Clinic this coming Monday for testing and to meet with physicians there.
I asked him to give me a write up of the timeline of his battle up to this point and I ask the wonderful board members here for any input or suggestions on what he might do to try to get Leronlimab into his treatment. The following is the past 4 years leading up to this point:
January 2022
Single episode of hematuria leads to CT scan of the abdomen and pelvis. This demonstrates left sided kidney mass measuring roughly 12 x 10 x 9 centimeters. Additional pre-operative imaging showed no evidence of metastatic disease.
February 2022
Surgical removal of the left kidney in totality by robotic-assisted nephrectomy at U of M Ann Arbor. Procedure tolerated well and patient was discharged the following day. Surgical pathology demonstrated renal cell carcinoma, classic clear-cell type (pT3a), WHO/ISUP nuclear grade 4. Tumor extends into the renal sinus fat. All surgical margins free of tumor. Adrenal gland shows no significant pathology. No lymphovascular invasion present. Lymph nodes negative (absent).
April 2022
Initiated nine rounds of prophylactic Keytruda infusion therapy. Stopped after the fifth infusion due to profound fatigue when it was determined patient was both thyroid and cortisol deficient. Patient still remains on supplemental levothyroxine and hydrocortisone at this time. It was elected to not finish Keytruda therapy. At the time patient remained free of any imaging evidence of metastatic disease.
March 2023
Routine follow-up CT scan of the chest demonstrates the beginning of appearance of millimeter sized lung legions increasing in size over the next three years. No additional imaging of evidence of metastatic cancer in the tumor bed or other remote sights. No active treatment undertaken at this point.
June 2024
Nuclear medicine PET scan demonstrates left hilar lymph node conglomerate suspicious for metastatic cancer. Bronchoscopy undertaken with FNA of suspicious lymph node conglomerate. Pathology demonstrates the aforementioned renal cell carcinoma (clear-cell type).
September 2024
Received 60 Gy via external beam stereotactic radiation in ten fractions over two weeks to the left hilum of the lung. Tolerated treatment without difficulty.
February 2025
Follow-up CT scan demonstrates increasing subcarinal metastatic disease.
June/July 2025
NM PET whole body scan shows enlarged and metabolically active subcarinal and right perihilar metastatic disease in the lymph node structures. It was determined to initiate Cabozantinib treatment at 80 mg daily. After two weeks, patient developed a severe episode of vascular crisis with symptoms of chest pain as well as neurologic changes. Cabozantinib was discontinued for a week and then restarted at 40 mg daily. Symptoms and side effects returned after one week despite anti-hypertensive therapy. Medication discontinued indefinitely.
September 2025
Initiated belzutifan 120 mg daily for treatment of metastatic renal cell carcinoma. Tolerated medication well with the exception of anemia, moderate in nature with hemoglobin declining to mid nines. O2 sats normal.
November 2025
Patient experienced episode of self-limited hemoptysis of significant amount (4 tablespoons). Emergency room work-up including CT of chest was negative. Referred to pulmonology who recommended bronchoscopy including potential cryoablation. Discovered two intraluminal lesions on scope which were treated by ablation. No further hemoptysis since.
December 2025
At follow up with medical oncology it was indicated that oncologist would not pursue further monoclonal antibody therapy due to danger of side effects in this patient. If further scans showed the belzutifan was ineffective then they would search for a trial to enroll the patient.
I know this is a lot of information, most of which I do not understand, but I know there are members on this board that do. Any and all suggestion on how we can get him on leronlimab is greatly appreciated. I am not sure if there are any doctors at the Mayo clinic in Rochester MN that have experience using Leronlimab but if there are the names would be phenomenal to have. Also, I am not sure what test CYDY requires a patient to have before they can apply for emergency use/compassionate use but that would be great to know as well.
I apologize for the length of this post, but if any of you had the privilege of witnessing first-hand the compassion and dedication this man has for helping and serving others like I have, you would do the same.
Thank you so much in advance for the responses. I have invested way more than I should in this company, but I, like others here, know what this amazing molecule can do. If I never see a dime of profit from this investment but it helps my brother-in-law, it was all worth it.
GLTAL!!!
LemonLime
I have been invested in CYDY since March of 2020. I work in an elderly care facility, and when covid hit I began doing as much research as I could on it. Like others on this board, my research led me to Leronlimab (LemonLime as my sister affectionately calls it hence the alias).
I wish my first post could be positive and upbeat, but unfortunately the diagnosis of cancer in a loved one is what prompted me to make an account.
My brother-in-law, who is a physician and has dedicated his life to helping others as a family practitioner, is heading to the Mayo Clinic this coming Monday for testing and to meet with physicians there.
I asked him to give me a write up of the timeline of his battle up to this point and I ask the wonderful board members here for any input or suggestions on what he might do to try to get Leronlimab into his treatment. The following is the past 4 years leading up to this point:
January 2022
Single episode of hematuria leads to CT scan of the abdomen and pelvis. This demonstrates left sided kidney mass measuring roughly 12 x 10 x 9 centimeters. Additional pre-operative imaging showed no evidence of metastatic disease.
February 2022
Surgical removal of the left kidney in totality by robotic-assisted nephrectomy at U of M Ann Arbor. Procedure tolerated well and patient was discharged the following day. Surgical pathology demonstrated renal cell carcinoma, classic clear-cell type (pT3a), WHO/ISUP nuclear grade 4. Tumor extends into the renal sinus fat. All surgical margins free of tumor. Adrenal gland shows no significant pathology. No lymphovascular invasion present. Lymph nodes negative (absent).
April 2022
Initiated nine rounds of prophylactic Keytruda infusion therapy. Stopped after the fifth infusion due to profound fatigue when it was determined patient was both thyroid and cortisol deficient. Patient still remains on supplemental levothyroxine and hydrocortisone at this time. It was elected to not finish Keytruda therapy. At the time patient remained free of any imaging evidence of metastatic disease.
March 2023
Routine follow-up CT scan of the chest demonstrates the beginning of appearance of millimeter sized lung legions increasing in size over the next three years. No additional imaging of evidence of metastatic cancer in the tumor bed or other remote sights. No active treatment undertaken at this point.
June 2024
Nuclear medicine PET scan demonstrates left hilar lymph node conglomerate suspicious for metastatic cancer. Bronchoscopy undertaken with FNA of suspicious lymph node conglomerate. Pathology demonstrates the aforementioned renal cell carcinoma (clear-cell type).
September 2024
Received 60 Gy via external beam stereotactic radiation in ten fractions over two weeks to the left hilum of the lung. Tolerated treatment without difficulty.
February 2025
Follow-up CT scan demonstrates increasing subcarinal metastatic disease.
June/July 2025
NM PET whole body scan shows enlarged and metabolically active subcarinal and right perihilar metastatic disease in the lymph node structures. It was determined to initiate Cabozantinib treatment at 80 mg daily. After two weeks, patient developed a severe episode of vascular crisis with symptoms of chest pain as well as neurologic changes. Cabozantinib was discontinued for a week and then restarted at 40 mg daily. Symptoms and side effects returned after one week despite anti-hypertensive therapy. Medication discontinued indefinitely.
September 2025
Initiated belzutifan 120 mg daily for treatment of metastatic renal cell carcinoma. Tolerated medication well with the exception of anemia, moderate in nature with hemoglobin declining to mid nines. O2 sats normal.
November 2025
Patient experienced episode of self-limited hemoptysis of significant amount (4 tablespoons). Emergency room work-up including CT of chest was negative. Referred to pulmonology who recommended bronchoscopy including potential cryoablation. Discovered two intraluminal lesions on scope which were treated by ablation. No further hemoptysis since.
December 2025
At follow up with medical oncology it was indicated that oncologist would not pursue further monoclonal antibody therapy due to danger of side effects in this patient. If further scans showed the belzutifan was ineffective then they would search for a trial to enroll the patient.
I know this is a lot of information, most of which I do not understand, but I know there are members on this board that do. Any and all suggestion on how we can get him on leronlimab is greatly appreciated. I am not sure if there are any doctors at the Mayo clinic in Rochester MN that have experience using Leronlimab but if there are the names would be phenomenal to have. Also, I am not sure what test CYDY requires a patient to have before they can apply for emergency use/compassionate use but that would be great to know as well.
I apologize for the length of this post, but if any of you had the privilege of witnessing first-hand the compassion and dedication this man has for helping and serving others like I have, you would do the same.
Thank you so much in advance for the responses. I have invested way more than I should in this company, but I, like others here, know what this amazing molecule can do. If I never see a dime of profit from this investment but it helps my brother-in-law, it was all worth it.
GLTAL!!!
LemonLime
29
